OTC Penny Stocks Volume Movers at Open TAON, CBAI, VVUS, ACTC, IGSM as Treasurys bonds are in a steep fall and stocks are headed to a higher opening as investors continue to size up President Barack Obama’s compromise to extend tax cuts for two years.
Dec 8, 2010 Boca Raton, FL–TheStockwizards.net analyzes the most notable explosive OTC, OTCBB, NASDAQ, NYSE Micro Cap Penny Stocks such as TAONwith huge volume and positive change.
The most active bullish small cap stocks at the open of trading includes: OTC: TAON, CBAI, VVUS, ACTC, IGSM
1-Tao Minerals Ltd. (TAON.PK) last .0143 up 14% on 14.6 million shares traded at the open.
TAON in a press release this morning announced that they have commenced the first phase geophysical review of the Mutata Gold and Platinum project. As part of the 90 day assessment period of the highly prospective Mutata project Tao has hired Senior Resource and Professional Geologist, James A. McCrea to lead this four-stage review. Mr. McCrea has more than 22 years experience in exploration and mining geology, and 15 years experience in mineral resource estimation. Jim’s experience was gained through working for junior mining/exploration companies and engineering firms SRK and Snowden.
Tao Minerals Ltd., an exploration stage company, engages in the acquisition, exploration, and development of natural resource properties in Columbia. It primarily explores for gold and silver.
2-Cord Blood America Inc. (CBAI.OB) last .0045 up 12% on 35.4 million shares traded at the open.CBAI was highlighted on the TSW weekly top 10 watchlist as a bottom reversal candidate this past weekend.
CBAI announced this morning that it has signed a letter of intent to purchase Cryo-Cell Mexico, which is Mexico’s largest stem cell storage company.
Cord Blood America, Inc., through its subsidiaries, provides private cord blood stem cell preservation services to families in the United States.
3-VIVUS Inc. (VVUS) last 9.06 up 15% on 11.2 million shares traded in the first 30 min.
In a shock to watchers of recent developments in the area of weight loss drugs, the FDA panel of expert advisors voted 13 to 7 recommending the approval of Contrave from Orexigen. They also voted 11 to 8 – with one member abstaining – that a long-term cardiovascular study should be conducted after approval of the drug.
VIVUS, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products for underserved markets in the United States
4- Advanced Cell Technology Inc. (ACTC.OB) last .176 up 10% on 18 million shares traded in the first 30 min. ACTC is up 70% this week from our profile on the TSW weekly top 10 watchlist.
Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine.
5-IGSM Group, Inc. (IGSM.PK) last .0024 up 26% on 32.2 million shares traded at the opening bell.
GSM Group Inc. focuses on providing outsourced digital services to various businesses. The company intends to operate digital television channels in Florida
About the Stock Wizards.net
TheStockwizards.net a free hot penny stock picks alert blog newsletter gives you up to the minute real-time detailed financial information with quotes and chart updates on the OTC-OTCBB, NYSE, and NASDAQ.
The TSW penny stock finder trading system locates the best small cap, micro cap penny stocks such as TAON that have unusual movements with news, popular small cap penny stocks with big gains, and strong stock trends.
The assembled information distributed by TheStockWizards.net is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. TheStockWizards.net does expect that investors will buy and sell securities based on information assembled and presented herein. TheStockWizards.net will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. Always do your own due diligence, and consult your financial advisor